Source content
FAA Guide for Aviation Medical Examiners · Version 10/28/2026 · page 775
Guide Official Revision Description Reason for Update
Version Date Number Of Change
named medication. Added
bimekizumab (Bimzelx) to
acceptable Interleukin
Inhibitors.
2026 08/26/2026 18 Medical Policy In Item 46. Neurologic,
revised CACI – Migraine and
Chronic Headache
Worksheet . Reduced
eletriptan (Relpax) and
frovatriptan (Frova) to 48
hours no fly, added
ondansetron (Zofran) with 24
hour no-fly, and reduced to
24 hour no fly time for
ubrogepant (Ubrelvy) and
Rimegepant (Nurtec).
2026 08/26/2026 19 Medical Policy In Pharmaceuticals, Migraine
Medications revised Pharm.
Migraine page. Reduced
post dose for migraine
treatment using
CGRP to 24 hours.
2026 08/26/2026 20 Medical Policy Revised AASI for Asthma to
removed 3 medication limit.
2026 08/26/2026 21 Medical Policy In Item 35. Lungs and Chest,
revised Chronic Obstructive
Pulmonary Disease (COPD),
Emphysema, Chronic
Bronchitis Disposition table
to clarify SpO2 is at rest on
room air.
2026 08/26/2026 22 Medical Policy In Item 41. G.U., revised Low
Testosterone (Low T)
hypogonadism Status
Summary to hematocrit
greater than 54%.
2026 08/26/2026 23 Medical Policy In Item 47. Psychiatric
Conditions, AASI for Anxiety,
Depression, and Related
Conditions clarified clinic visit
requirements.
2026 08/26/2026 24 Medical Policy In Pharmaceuticals, updated
Osteoporosis Medications to
add bazedoxifene (Duavee).
Shown as extracted from the FAA PDF, without paraphrasing. Tables and forms may lose their layout. Underlined references open the Guide location they name.
